




REDUCTION IN INFLAMMATORY AND NONINFLAMMATORY ACNE¹

TAZORAC[®] (tazarotene) CREAM 0.1% vs vehicle



Results of 2 large, vehicle-controlled studies (of patients aged 12 years or older) comparing TAZORAC Cream 0.1% and vehicle cream.



Adverse events

The most frequent adverse reactions reported during clinical trials with TAZORAC Cream 0.1% in the treatment of acne, occurring in 10% to 30% of patients, in descending order, included desquamation, dry skin, erythema, and burning sensation.

Events occurring in 1% to 5% of patients included pruritus, irritation, face pain, and stinging.

TAZORAC[®]
(tazarotene) Cream and Gel 0.1%


TAZORAC[®] (tazarotene) GEL 0.1% vs vehicle



Results of 2 large, vehicle-controlled studies (of patients aged 12 years or older) comparing TAZORAC Gel 0.1% and vehicle gel.

GAAS RESULTS³

PERCENTAGE OF SUBJECTS WITH A TREATMENT SUCCESS RATE OF $\geq 50\%$ IMPROVEMENT AT 12 WEEKS—STUDIES 1 AND 2



Adverse events

The most frequent adverse reactions reported during clinical trials with TAZORAC Gel 0.1% in the treatment of acne, occurring in 10% to 30% of patients, in descending order, included desquamation, burning/stinging, dry skin, erythema, and pruritus.

Events occurring in 1% to 10% of patients included irritation, skin pain, fissuring, localized edema, and skin discoloration.

References: 1. Tazorac Cream and Gel 0.1% and 0.05% Prescribing Information; August 2019. 2. Shalita AR, Berson DS, Thiboutot DM, et al; for Tazarotene Cream in Acne Clinical Study Investigator Group. Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. *Clin Ther*. 2004;26(11):1865-1873. 3. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. *Cutis*. 1999;63(6):349-354.